GHRP-6: Clinical Guide for Prescribing Practices
GHRP-6 is a first-generation synthetic hexapeptide growth hormone secretagogue that strongly activates the ghrelin receptor. It produces strong GH release with the most pronounced appetite stimulation of any GHRP, making it particularly useful when weight gain is a treatment goal alongside GH optimization.
Also Known As
How GHRP-6 Works
GHRP-6 is a first-generation synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that potently activates the growth hormone secretagogue receptor (GHS-R1a), the endogenous ghrelin receptor [1]. Its binding produces strong activation of both hypothalamic GH-releasing pathways and the appetite centers in the arcuate nucleus [2]. GHRP-6 stimulates GH release through calcium-dependent signaling in pituitary somatotrophs while simultaneously suppressing somatostatin release, producing a strong but less selective GH pulse compared to newer secretagogues [4].
Clinical Evidence
GHRP-6 was one of the first synthetic GH secretagogues characterized in clinical research [1]. Human studies demonstrate potent, reproducible GH release with peak levels occurring within 15 to 30 minutes of subcutaneous administration [4]. Comparative data show GHRP-6 produces the strongest appetite stimulation of any GHRP due to potent ghrelin-pathway activation [2]. It elevates cortisol and prolactin more than GHRP-2 or ipamorelin [3]. The synergistic combination with GHRH analogs was first demonstrated with GHRP-6, establishing the dual-pathway protocol paradigm used with all modern GH peptide combinations [1].
Clinical Uses
Patient Selection and Screening
GHRP-6 is specifically indicated when appetite stimulation and weight gain are desirable therapeutic outcomes alongside GH optimization: cachexia, sarcopenia with underweight, post-surgical failure to thrive, and poor oral intake recovery [2]. Avoid in patients actively trying to lose weight, those with insulin resistance or metabolic syndrome [3], and patients with anxiety disorders (cortisol concerns). Screen with baseline IGF-1, cortisol, prolactin, fasting glucose, and comprehensive metabolic panel. Not first-line for patients who simply want GH optimization without appetite effects.
Dosing and Administration
Standard dosing is 100 to 300mcg subcutaneously, 2 to 3 times daily on an empty stomach [4]. Intense hunger typically occurs 20 to 30 minutes post-injection; counsel patients accordingly [2]. Most effective when combined with CJC-1295 (100 to 200mcg) or sermorelin (200 to 300mcg) for synergistic GH release [1]. Start at 100mcg and titrate upward as tolerated. The appetite effect does not diminish significantly with continued use. Cycling (8 to 12 weeks on, 4 weeks off) is advisable to prevent receptor desensitization. Evening dosing aligns with nocturnal GH physiology but may cause nighttime hunger. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection, typically 100-300mcg 2-3 times daily on an empty stomach. Often stacked with CJC-1295 for amplified GH pulse. The pronounced hunger typically peaks 20-30 minutes post-injection.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
GHRP-6 is one of the lowest-cost GH peptides available, with wholesale pricing typically under $30 per vial. Patient pricing for GHRP-6 protocols ranges from $150 to $300 per month. Its niche positioning for appetite stimulation and weight gain [2] makes it valuable for specific patient populations (cachexia, post-surgical recovery) where other GH peptides are less appropriate. Volume is typically lower than ipamorelin-based protocols, but it provides important clinical versatility in a full GH peptide program menu.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe GHRP-6 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
When is GHRP-6 preferred over other GH peptides?
How significant is the appetite stimulation from GHRP-6?
References
- Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984;114(5):1537-1545
- Arvat E et al. GHRP-6 and appetite stimulation in humans. J Endocrinol Invest. 1995;18(2):132-136
- Broglio F et al. Ghrelin and the endocrine pancreas. Endocrine. 2001;14(1):11-14
- Peino R et al. GHRP-6 induces a potent and reproducible rise in GH in humans. Eur J Endocrinol. 1996;134(3):352-356
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe GHRP-6 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe GHRP-6 Through Karpa